Aurobindo Pharma Ltd (AUROPHARMA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Aurobindo Pharma Ltd on NSE and BSE, with an AI summary of each filing.
Submission of Financial results for the Quarter and Half year ended September 30, 2026.
Financial Result · 05 Nov 2026, 2:18 am
Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027.
Change in Management · 05 Nov 2026, 2:08 am
Aurobindo Pharma Re-Appoints M. R. Kumar as Independent Director for Five Years Aurobindo Pharma's Board approved the re-appointment of Mr. Mangalam Ramasubramanian Kumar as Non-Executive and Independent Director for a second five-year term effective 1st Apr'27, upon the completion of his initial term on 31st Mar'27. The re-appointment is subject to shareholder approval via special resolution through postal ballot. Mr. Kumar, a former Chairman of LIC of India and current Non-Executive Chairman of Bank of India, is not liable to retire by rotation and has no relationships with any director or Key Managerial Personnel of the company.
Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company.
Others (Uncategorized) · 05 Nov 2026, 2:04 am
Aurobindo Pharma Approves Internal Reorganization of Russian Subsidiary for INR 29 Crore Aurobindo Pharma approved the transfer of 100% ownership in its Russian step-down subsidiary, Auro Pharma LLC, from Auro Active Pharma Private Limited to Auropharm Overseas Limited, both wholly owned subsidiaries. Undertaken at an arm’s length cash consideration of ~INR 29 crore, the transaction is an internal reorganization to streamline Russian holdings. Auro Pharma LLC, incorporated on 24th Jul'23 for manufacturing and marketing pharmaceuticals, reported nil turnover across FY24–FY26. The acquisition requires no regulatory approvals and is slated for completion within 60–90 days.
Approved the proposal of Merger of two wholly owned subsidiaries of the Company.
Others (Uncategorized) · 05 Nov 2026, 1:58 am
Aurobindo Pharma Approves Merger of Wholly Owned API Subsidiaries Aurobindo Pharma’s board approved a Scheme of Amalgamation to merge its wholly owned subsidiary Auroactive Pharma (FY26 turnover: INR 701.3m) into Apitoria Pharma (FY26 turnover: INR 64,430.8m), subject to NCLT Hyderabad approval. The swap ratio is set at 97 equity shares of Apitoria Pharma for every 10,000 shares of Auroactive Pharma, totaling 2,395,900 shares. The consolidation aims to integrate API operations, optimize capacity utilization, and simplify group structure, with no change to the parent company's shareholding pattern.
Intimation of record date for payment of interim dividend for FY 2026-2027.
Dividend · 05 Nov 2026, 1:50 am
Aurobindo Pharma Approves 700% Interim Dividend for FY 2026-27 Aurobindo Pharma's Board of Directors approved an interim dividend of 700%, amounting to Rs. 7.00 per equity share of Re. 1.00 face value for FY27. The record date to determine shareholder eligibility has been set for 11th Nov'26. The company confirmed that the interim dividend payout will be completed on or before 20th Nov'26.
Intimation of declaration of interim dividend for FY 2026-27.
Dividend · 05 Nov 2026, 1:46 am
Aurobindo Pharma Approves 700% Interim Dividend for FY27 Aurobindo Pharma’s Board of Directors has declared an interim dividend of 700%, translating to Rs. 7.00 per equity share with a face value of Re. 1.00 for FY27. The company has fixed 11th Nov'26 as the record date to determine shareholder eligibility. The interim dividend is scheduled to be paid on or before 20th Nov'26.
Submission of Earnings Presentation on Q2 FY27 Financial Results.
Investor Presentation · 05 Nov 2026, 1:35 am
Aurobindo Pharma Delivers Strong Q2FY27 Results with Record Revenue and Margins Aurobindo Pharma reported its highest-ever quarterly revenue of ₹10,263 Cr in Q2FY27, up 23.9% YoY and 12.2% QoQ, driven by solid formulation growth across the US (+25.2% YoY) and Europe (+27.5% YoY). EBITDA reached a record ₹2,156 Cr (+28.5% YoY) with margins expanding 75 bps YoY to 21.0%, while PAT rose 32.5% YoY to ₹1,124 Cr. The company completed the Lannett acquisition, generated US$ 146mn in net cash flow, and maintained a net cash position of ~US$ 189mn as of 30th Sep'26.
Submission of Press Release on Q2 FY27 financial results
Press Release · 05 Nov 2026, 1:33 am
Aurobindo Pharma Delivers Strong Q2FY27 Results With 32.5% YoY PAT Growth Aurobindo Pharma reported its highest-ever quarterly revenue of INR 10,263 Cr in Q2FY27, up 23.9% YoY (12.2% QoQ). EBITDA grew 28.5% YoY to INR 2,156 Cr with margins expanding 75 bps YoY to 21.0%. Net profit surged 32.5% YoY to INR 1,124 Cr. US revenue rose 25.2% YoY to INR 4,555 Cr, while Europe grew 27.5% YoY to INR 3,161 Cr. The company generated USD 146 million in free cash flow, held net cash of USD 189 million as of 30th Sep'26, and declared an interim dividend of INR 7.0 per share.
Submission of outcome of Board Meeting held on November 4, 2026
Outcome · 05 Nov 2026, 1:29 am
Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 05 Nov 2026, 1:23 am
Aurobindo Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 1,02,633 (+23.9% YoY | +12.2% QoQ) ■ EBITDA: 21,558 (+28.5% YoY | +14.6% QoQ) ■ EBITDA Margin (%): 21.0 (+75 bps YoY | +45 bps QoQ) ■ PAT: 11,261 (+32.7% YoY | +9.1% QoQ) ■ EPS (INR): 19.6 (+33.9% YoY | +9.6% QoQ)
Intimation of Earnings Call scheduled to be held on November 5, 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026.
Intimation · 05 Nov 2026, 8:30 am
Aurobindo Pharma Schedules Q2 & H1FY27 Earnings Call for 5th Nov'26 Aurobindo Pharma Limited has scheduled an earnings call for analysts and investors on 5th Nov'26 at 8:30 AM IST. The call will discuss the company's unaudited financial results for the second quarter and half year ended 30th Sep'26 (Q2FY27). An earnings presentation will be made available on the company's website following the results announcement. Pre-registration for the call is accessible via Zoom.
AUROBINDO PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Dividend.
Intimation · 04 Nov 2026, 5:30 am
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....
Intimation · 04 Nov 2026, 5:30 am
Aurobindo Pharma Board to Consider Q2 Results and Interim Dividend Aurobindo Pharma's Board of Directors is scheduled to meet on 4th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended 30th Sep'26. Additionally, the board will evaluate the declaration of an interim dividend for FY27. In compliance with insider trading regulations, the company's trading window remains closed until 6th Nov'26 and will reopen on 7th Nov'26.
To consider and approve the financial results for the period ended September 30, 2026 and dividend
Intimation · 04 Nov 2026, 5:30 am
Submission of Press Release that is being issued by the Company in connection with receipt of USFDA final approval for Perampanel Tablets 2 mg, 4 mg, 6 mg, 8 mg 10 mg and 12 mg.
Press Release · 03 Oct 2026, 10:39 pm
Aurobindo Pharma Secures USFDA Final Approval for Generic Fycompa Tablets Aurobindo Pharma received USFDA final approval on 3rd Oct'26 to manufacture and market Perampanel Tablets (2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg), bioequivalent to Catalyst Pharmaceuticals' Fycompa. Indicated for epilepsy seizures, the product addresses a US$ 67 million market (IQVIA MAT Aug'26). Manufacturing will occur at wholly owned subsidiary APL Healthcare's Unit-IV, with a planned launch in Q3FY27. This brings Aurobindo's cumulative USFDA tally to 599 ANDA approvals, comprising 574 final and 25 tentative approvals.
Intimation of completion of acquisition.
Others (Uncategorized) · 03 Oct 2026, 12:05 am
Aurobindo Pharma Subsidiary Apitoria Completes A1 Biochem Acquisition to Strengthen CRDMO Business Aurobindo Pharma announced that its wholly owned subsidiary, Apitoria Pharma, completed the acquisition of A1 Biochem Group's contract research services business on 2nd Oct'26. Apitoria now holds an 80% stake in A1 Biochem Labs (India), while former promoter Dr. Rajendra Gadikota retains 20%. Concurrently, A1 Labs India acquired 100% of US-based A1 Biochem Labs LLC. The transaction provides Apitoria access to an established CRO platform with 50+ clients and 800+ completed projects, advancing its transition into an integrated CRDMO platform across India and the US.
Intimation of acquisition of a step down subsidiary in USA.
Others (Uncategorized) · 02 Oct 2026, 11:39 pm
Aurobindo Pharma Acquires US-Based A1 Biochem Labs LLC for USD 15.247 Mn Aurobindo Pharma's step-down subsidiary, A1 Biochem USA Inc, acquired 100% ownership of US-based A1 Biochem Labs LLC for a cash consideration of USD 15.247 Mn on 2nd Oct'26. The target provides contract research and chemistry services, reporting revenues of USD 6.35 Mn, USD 9.23 Mn, and USD 5.92 Mn across CY23, CY24, and CY25, respectively. The transaction bolsters Aurobindo’s front-end R&D capabilities, enabling the creation of an integrated CRDMO platform alongside its existing large-scale API manufacturing business.
Intimation of allotment of shares by A1 Biochem Labs (India) Private Limted, a step down subsidiary of the Company.
Others (Uncategorized) · 01 Oct 2026, 6:24 pm
Aurobindo Pharma Dilutes Stake in Step-Down Subsidiary A1 Biochem Labs Aurobindo Pharma’s wholly owned subsidiary, Apitoria Pharma, diluted its holding in step-down subsidiary A1 Biochem Labs from 100% to 80% on a fully diluted basis. Former promoter Dr. Rajendra Gadikota subscribed to 89,94,500 equity shares (INR 9.18 Cr) and 2,41,05,500 Compulsory Convertible Debentures (INR 24.62 Cr), securing a 20% stake for INR 33.80 Cr on 30th Sep'26. A1 Labs remains a subsidiary, with Apitoria retaining an option to reacquire the 20% stake in the future under agreed definitive terms.
Submission of press release that is being issued by the Company in connection with launching of ADQUEY in the U.S and Establishes Dedicated Dermatology Business.
Press Release · 01 Oct 2026, 2:58 am
Aurobindo Pharma Subsidiary Launches ADQUEY in US, Targets $1.3B Dermatology Market Aurobindo Pharma’s step-down subsidiary, Acrotech Biopharma, launched ADQUEY (difamilast 1% ointment) in the U.S. on 30th Sep'26, marking its strategic entry into dermatology. Discovered by Otsuka Pharmaceutical and licensed to Acrotech, the non-steroidal topical PDE4 inhibitor treats mild-to-moderate atopic dermatitis in patients aged two and older. The product addresses an addressable U.S. market estimated at US$ 1.3 billion for the MAT ending Jul'26 (IQVIA). To support commercialization, Acrotech established a dedicated dermatology business unit covering marketing, sales, and field engagement.
Intimation of order passed by Appellate Joint Commissioner (ST), Malkajgiri Division, Hyderabad, Telangana.
Others (Uncategorized) · 29 Sept 2026, 10:15 pm
Aurobindo Pharma Faces ₹4.60 Crore Tax Demand via Appellate Order Aurobindo Pharma received an order dated 28th Sep'26 from the Appellate Joint Commissioner (ST), Hyderabad, confirming a total disputed demand of ₹4.60 crore for FY21. This comprises a tax reversal of ₹2.56 crore for alleged excess Input Tax Credit claims, ₹1.78 crore in interest, and a ₹0.26 crore penalty. The company plans to appeal the order before the GST Appellate Tribunal and stated the ruling has no material impact on its financials or operations.
Intimation of investor Analyst meet scheduled on 24.09.2026.
Intimation · 21 Sept 2026, 9:35 pm
Aurobindo Pharma to Participate in JP Morgan Healthcare Investor Meeting Aurobindo Pharma officials are scheduled to participate in a group investor/analyst meeting at the JP Morgan Healthcare Trip in Hyderabad on 24th Sep'26, from 02:30 PM to 03:30 PM IST. The company confirmed that no unpublished price sensitive information (UPSI) will be discussed during the interaction.
Submission of completion of US FDA inspection of Unit-II of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
Others (Uncategorized) · 15 Sept 2026, 11:44 pm
Aurobindo Pharma Subsidiary Unit-II Concludes US FDA Inspection with One Procedural Observation The US FDA concluded an inspection of Unit-II, an API manufacturing facility of Apitoria Pharma Private Limited—a wholly owned subsidiary of Aurobindo Pharma—located at Kazipally Industrial Area, Telangana, conducted between 7th Sep'26 and 15th Sep'26. The inspection closed with one procedural observation. The company stated it will submit a response to the US FDA within the stipulated timeline while maintaining robust quality and compliance standards across its manufacturing operations.
Submission of Press Release that is being issued in connection with receipt of US FDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol , 40 mcg and 80 mcg.
Press Release · 15 Sept 2026, 6:40 pm
Aurobindo Pharma Secures USFDA Approval for First Complex MDI Inhaler Aurobindo Pharma received USFDA final approval on 15th Sep'26 for Beclomethasone Dipropionate HFA Inhalation Aerosol (40 mcg and 80 mcg), a generic equivalent of Teva’s QVAR. Marking Aurobindo’s first metered-dose inhaler product, it will be manufactured at subsidiary Aurolife Pharma's North Carolina facility with launches slated for upcoming quarters. According to IQVIA, the relevant US market was valued at US$301 million for the 12 months ended Jul'26. This expands Aurobindo's cumulative USFDA ANDA portfolio to 596 approvals (571 final, 25 tentative).
Intimation of subscription of 10,000 shares of USD 100 each of A1 Biochem USA Inc by A1 Biochem Labs (India) Private Limited, a step down subsidiary of the Company.
Others (Uncategorized) · 12 Sept 2026, 6:20 pm
Aurobindo Pharma Step-Down Subsidiary Subscribes to 100% Capital in A1 Biochem USA Aurobindo Pharma's step-down subsidiary, A1 Biochem Labs (India) Private Limited, subscribed to 10,000 equity shares of newly incorporated A1 Biochem USA Inc at USD 100 per share on 11th Sep'26, totaling a cash consideration of USD 1 mn. Following the subscription, A1 Biochem USA Inc is a 100% wholly owned subsidiary established to conduct Contract Research and Development (CRO/CDMO) services in the US. The transaction aligns with Aurobindo's earlier disclosed acquisition of the A1 Biochem Group on 23rd Jul'26.
Intimation of completion of US FDA inspection of Unit-IV of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
Others (Uncategorized) · 11 Sept 2026, 11:04 pm
US FDA Concludes Unit-IV Inspection of Aurobindo Pharma Subsidiary with Zero Observations The US FDA inspected Unit-IV, an API manufacturing facility of Aurobindo Pharma's wholly owned subsidiary, Apitoria Pharma Private Limited, located at Pydibhimavaram, Srikakulam District, Andhra Pradesh. Conducted from 7th Sep'26 to 11th Sep'26, the regulatory audit concluded successfully with zero observations, underscoring the facility's compliance with robust quality and manufacturing standards.